how to exchange digital currency- Top Featured

Lexin Technology's daily limit of 20cm today was 192 million yuan, and Lexin Technology's daily limit was 20cm today, with a turnover of 2.799 billion yuan and a turnover rate of 12.22%. After-hours data showed that the special seats of Shanghai Stock Connect bought 215 million yuan and sold 226 million yuan, and the special seats of the two institutions sold 192 million yuan.The Hunan Provincial People's Procuratorate decided to arrest Lei Chunyong according to law. The case of Lei Chunyong (deputy department level), the former deputy secretary and vice chairman of the political consultative conference in Chenzhou City, Hunan Province, who was suspected of taking bribes and using his influence, was investigated by the Hunan Provincial Supervision Commission and transferred to the procuratorate for review and prosecution. A few days ago, the Hunan Provincial People's Procuratorate made an arrest decision on Lei Chunyong on suspicion of accepting bribes and using influence to accept bribes. The case is being further processed.Nissan Motor Co., Ltd. reorganized its top management: CFO will be transferred to China to take charge of operations, and Nissan Motor Co., Ltd. is reorganizing its top management, hoping to introduce new talents and reverse the company's declining profits, increasing debts and lack of revenue-generating products. Makoto Uchida will continue to be the CEO of Nissan, while Jeremie Papin will be the CFO at the end of next year, and Christian Meunier will succeed Papin as the chairman of Nissan Americas. In addition, Stephen Ma, the company's chief financial officer, will be transferred to China to take charge of local business operations.

Guotai Junan expects Hong Kong stocks to fluctuate upward in an N-shaped pattern next year to explore domestic demand and improve investment opportunities. Chen Ximiao, chief analyst of Guotai Junan's overseas strategy, said that looking forward to 2025, the disturbance factors in the Hong Kong stock market from the external environment will continue, and the pace of interest rate cuts by the Federal Reserve under overseas inflation, policy restrictions in areas such as strong US dollar and tariffs, and game friction among big countries will continue. However, the domestic policy thinking is clear, economic expectations are expected to stabilize under the financial impetus, and the profitability of molecular enterprises will improve, and the industrial chain will be able to cope with it. She said that in 2025, the sensitivity of the Hong Kong stock market to external shocks is expected to decline, and more attention should be paid to returning to its own logic. For the trend of Hong Kong stocks in 2025, it is expected to be dominated by the upward pattern of N-shaped shocks, and there are many opportunities for flexibility during the stage. In 2025, we should still actively look for the structure, and focus on the barbell strategy to shift the weight of the two ends. We need to pay more attention to the configuration rhythm and pay attention to the repair opportunities of some domestic products.AKIRA AMARI, a former Japanese parliamentarian, said that relying on TSMC alone for high-end chips is the biggest risk.Comments on Hong Kong stocks: Hang Seng Index fell by 0.77%, Hang Seng Technology Index fell by 1.31%, Hong Kong stocks closed, Hang Seng Technology Index fell by 0.77%, Hang Seng Technology Index fell by 1.31%, dropped by over 5%, and JD.COM Group and Meituan fell by over 2%.

Lexin Technology's daily limit of 20cm today was 192 million yuan, and Lexin Technology's daily limit was 20cm today, with a turnover of 2.799 billion yuan and a turnover rate of 12.22%. After-hours data showed that the special seats of Shanghai Stock Connect bought 215 million yuan and sold 226 million yuan, and the special seats of the two institutions sold 192 million yuan.Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.Governor of Belgorod, Russia: Ukrainian troops fired more than 30 shells in Belgorod within 24 hours, causing no casualties or property losses.